Home › Compare › OVIT vs ORCC

OVIT vs ORCC: Dividend Comparison 2026

OVIT yields 2000000.00% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OVIT wins by $4.879226400974806e+39M in total portfolio value
10 years
OVIT
OVIT
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full OVIT calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — OVIT vs ORCC

📍 OVIT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOVITORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OVIT + ORCC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
OVIT pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OVIT
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, OVIT beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OVIT + ORCC for your $10,000?

OVIT: 50%ORCC: 50%
100% ORCC50/50100% OVIT
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

OVIT
No analyst data
Altman Z
-921.4
Piotroski
1/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OVIT buys
0
ORCC buys
0
No recent congressional trades found for OVIT or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOVITORCC
Forward yield2000000.00% ✓9.79%
Annual dividend / share$2.00 ✓$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0% ✓-50%
Portfolio after 10y$4.879226400974806e+39M$21.4K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$1.04
Total dividends collected$4.879195005460081e+39M ✓$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: OVIT vs ORCC ($10,000, DRIP)

YearOVIT PortfolioOVIT Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,190$489.61+$200.00M → OVIT
2$3,738,731,768,458$3,738,517,757,009.35$12,229$256.01+$3738731.76M → OVIT
3$65,315,062,866,930,490$65,311,062,423,938,240.00$13,216$130.74+$65315062866.92M → OVIT
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$14,207$66.02+$1066400830062625.00M → OVIT
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$15,234$33.17+$16272182796453826560.00M → OVIT
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$16,317$16.62+$2.3205424011366188e+23M → OVIT
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$17,468$8.32+$3.0927990661046884e+27M → OVIT
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$18,695$4.16+$3.8524105697352695e+31M → OVIT
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$20,006$2.08+$4.484688260147987e+35M → OVIT
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$21,407$1.04+$4.879226400974806e+39M → OVIT

OVIT vs ORCC: Complete Analysis 2026

OVIT — Stock

OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.

Full OVIT Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this OVIT vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OVIT vs SCHDOVIT vs JEPIOVIT vs OOVIT vs KOOVIT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.